Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Gregory G Schwartz

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/399-8020

    Collapse Research 
    Collapse research activities and funding
    K11HL002155     (SCHWARTZ, GREGORY G)Sep 1, 1988 - Aug 31, 1993
    NIH/NHLBI
    METABOLIC CONTROL OF CORONARY FLOW--31P NMR SPECTROSCOPY
    Role: Principal Investigator

    R56HL049944     (SCHWARTZ, GREGORY G)Feb 1, 1994 - May 31, 2009
    NIH/NHLBI
    Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Role: Principal Investigator

    R01HL049944     (SCHWARTZ, GREGORY G)Feb 1, 1994 - May 31, 2014
    NIH/NHLBI
    Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lu L, Ye S, Scalzo RL, Reusch JEB, Greyson CR, Schwartz GG. Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs. Diabetologia. 2017 May 11. PMID: 28497164.
      View in: PubMed
    2. Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692. Diabetes Care. 2017 Apr; 40(4):e47-e48. PMID: 28325804.
      View in: PubMed
    3. Schwartz GG. Who Should Receive Ezetimibe? J Am Coll Cardiol. 2017 Feb 28; 69(8):922-923. PMID: 28231943.
      View in: PubMed
    4. Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. Circulation. 2017 May 16; 135(20):1882-1893. PMID: 28246237.
      View in: PubMed
    5. London MJ, Schwartz GG, Hur K, Henderson WG. Association of Perioperative Statin Use With Mortality and Morbidity After Major Noncardiac Surgery. JAMA Intern Med. 2017 Feb 01; 177(2):231-242. PMID: 27992624.
      View in: PubMed
    6. Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther. 2017 Feb; 7(1):45-51. PMID: 28164012.
      View in: PubMed
    7. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 Jan 10; 6(1). PMID: 28073769.
      View in: PubMed
    8. Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol. 2017 Jan 01; 2047487317708677. PMID: 28504565.
      View in: PubMed
    9. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, Kittelson J, Schwartz GG. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 Dec 06; 68(22):2488-2490. PMID: 27908356.
      View in: PubMed
    10. Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care. 2016 Oct; 39(10):1684-92. PMID: 27465265; PMCID: PMC5033078 [Available on 10/01/17].
    11. Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boulé M, Alem S, Grégoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rhéaume E, Dubé MP. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Circ Cardiovasc Genet. 2016 Aug; 9(4):340-8. PMID: 27418594; PMCID: PMC4982759.
    12. Nordmann A, Schwartz G, Vale N, Bucher HC, Briel M. Cochrane corner: early statin therapy in acute coronary syndromes--what is the clinical benefit? Heart. 2016 May; 102(9):653-4. PMID: 26908101.
      View in: PubMed
    13. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Apr 07; 374(14):1321-31. PMID: 26886418; PMCID: PMC4887756 [Available on 10/07/16].
    14. Niesor EJ, Benghozi R, Amouyel P, Ferdinand KC, Schwartz GG. Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease. Cardiovasc Drugs Ther. 2015 Dec; 29(6):563-572. PMID: 26619842.
      View in: PubMed
    15. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015 Jun 02; 65(21):2267-75. PMID: 26022813.
      View in: PubMed
    16. Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. Am Heart J. 2015 Jul; 170(1):117-22. PMID: 26093872.
      View in: PubMed
    17. Niesor EJ, Schwartz GG, Perez A, Stauffer A, Durrwell A, Bucklar-Suchankova G, Benghozi R, Abt M, Kallend D. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther. 2015 Feb; 29(1):7-14. PMID: 25749868.
      View in: PubMed
    18. Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015 Apr; 8(2):372-82. PMID: 25583994.
      View in: PubMed
    19. Do RQ, Nicholls SJ, Schwartz GG. Evolving targets for lipid-modifying therapy. EMBO Mol Med. 2014 Oct; 6(10):1215-30. PMID: 25172365; PMCID: PMC4287928.
    20. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2014 Sep 01; (9):CD006870. PMID: 25178118.
      View in: PubMed
    21. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9. PMID: 25440796.
      View in: PubMed
    22. Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J. 2014 Dec; 168(6):823-9.e6. PMID: 25458644; PMCID: PMC4254508.
    23. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16; 311(15):1515-25. PMID: 24682069.
      View in: PubMed
    24. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15; 311(3):252-62. PMID: 24247616.
      View in: PubMed
    25. London MJ, Schwartz GG, Henderson WG. Mortality after perioperative ß-blocker use in noncardiac surgery-reply. JAMA. 2013 Aug 14; 310(6):646. PMID: 23942690.
      View in: PubMed
    26. Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EP, Li M, Leusink M, Trompet S, Verschuren JJ, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van 't Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JM, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day IN, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JC, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Paré G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJ. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19; 62(21):1966-76. PMID: 23916927; PMCID: PMC3826105.
    27. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor a/? agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013 Sep; 166(3):429-34. PMID: 24016490.
      View in: PubMed
    28. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative ß-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA. 2013 Apr 24; 309(16):1704-13. PMID: 23613075.
      View in: PubMed
    29. Low Wang CC, Lu L, Leitner JW, Sarraf M, Gianani R, Draznin B, Greyson CR, Reusch JE, Schwartz GG. Arterial insulin resistance in Yucatan micropigs with diet-induced obesity and metabolic syndrome. J Diabetes Complications. 2013 Jul-Aug; 27(4):307-15. PMID: 23558108; PMCID: PMC3696427.
    30. Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep. 2013 Mar; 15(3):345. PMID: 23338726.
      View in: PubMed
    31. Schwartz GG, Olsson AG, Barter PJ. Dalcetrapib in patients with an acute coronary syndrome. N Engl J Med. 2013 Feb 28; 368(9):869-70. PMID: 23445098.
      View in: PubMed
    32. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013 Jan 28; 2(1):e003103. PMID: 23525424; PMCID: PMC3603244.
    33. Huang JV, Lu L, Ye S, Bergman BC, Sparagna GC, Sarraf M, Reusch JE, Greyson CR, Schwartz GG. Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. Am J Physiol Heart Circ Physiol. 2013 Mar 15; 304(6):H861-73. PMID: 23335793; PMCID: PMC3602770.
    34. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99. PMID: 23126252.
      View in: PubMed
    35. Huang JV, Greyson CR, Schwartz GG. PPAR-? as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res. 2012 Sep; 53(9):1738-54. PMID: 22685322; PMCID: PMC3413217.
    36. Sarraf M, Lu L, Ye S, Reiter MJ, Greyson CR, Schwartz GG. Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. Cardiovasc Drugs Ther. 2012 Jun; 26(3):195-204. PMID: 22450779.
      View in: PubMed
    37. Ahmad HA, Lu L, Ye S, Schwartz GG, Greyson CR. Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. Am J Respir Cell Mol Biol. 2012 Sep; 47(3):379-86. PMID: 22582173; PMCID: PMC3488694.
    38. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012 Feb; 26(1):71-5. PMID: 22109255.
      View in: PubMed
    39. Schwartz GG. New horizons for cholesterol ester transfer protein inhibitors. Curr Atheroscler Rep. 2012 Feb; 14(1):41-8. PMID: 22083134.
      View in: PubMed
    40. Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012 Feb 14; 125(6):757-66. PMID: 22230483.
      View in: PubMed
    41. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills E, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2011 Jun 15; (6):CD006870. PMID: 21678362.
      View in: PubMed
    42. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011 May; 161(5):993-9. PMID: 21570534.
      View in: PubMed
    43. Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, Ostadal P, Macin SM, Liem A, Mills E, Bhatnagar N, Bucher HC, Nordmann AJ. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2012 Jun 28; 158(1):93-100. PMID: 21295870.
      View in: PubMed
    44. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec; 158(6):896-901.e3. PMID: 19958854.
      View in: PubMed
    45. Schwartz GG. High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):46E-51E. PMID: 19895944.
      View in: PubMed
    46. Lee J, Xu Y, Lu L, Bergman B, Leitner JW, Greyson C, Draznin B, Schwartz GG. Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity. Am J Physiol Heart Circ Physiol. 2010 Feb; 298(2):H310-9. PMID: 19897715; PMCID: PMC2822577.
    47. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96. PMID: 19497447.
      View in: PubMed
    48. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis. 2009 Oct; 206(2):551-5. PMID: 19394618.
      View in: PubMed
    49. Lu L, Reiter MJ, Xu Y, Chicco A, Greyson CR, Schwartz GG. Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia. 2008 Apr; 51(4):675-85. PMID: 18251006; PMCID: PMC3633423.
    50. Schwartz GG. Lipid management after acute coronary syndrome. Curr Opin Lipidol. 2007 Dec; 18(6):626-32. PMID: 17993807.
      View in: PubMed
    51. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7. PMID: 17991875.
      View in: PubMed
    52. Greyson CR, Schwartz GG, Lu L, Ye S, Helmke S, Xu Y, Ahmad H. Calpain inhibition attenuates right ventricular contractile dysfunction after acute pressure overload. J Mol Cell Cardiol. 2008 Jan; 44(1):59-68. PMID: 18068185; PMCID: PMC2268883.
    53. Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol. 2007 Mar 01; 99(5):632-5. PMID: 17317362.
      View in: PubMed
    54. Sullivan A, Chmura K, Cool CD, Keith R, Schwartz GG, Chan ED. Pulmonary capillary hemangiomatosis: an immunohistochemical analysis of vascular remodeling. Eur J Med Res. 2006 May 05; 11(5):187-93. PMID: 16723291.
      View in: PubMed
    55. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikçioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006 May 03; 295(17):2046-56. PMID: 16670413.
      View in: PubMed
    56. Schwartz G, Singh D. Intensive statin therapy reduces clinical events at 30 days and after six months in acute coronary syndromes. Evid Based Cardiovasc Med. 2006 Mar; 10(1):35-7. PMID: 16530675.
      View in: PubMed
    57. Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, Bristow MR, Long CS, Schwartz GG. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1798-807. PMID: 16339839; PMCID: PMC3633446.
    58. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 Oct; 28(10):2508-13. PMID: 16186288.
      View in: PubMed
    59. Schwartz GG, Olsson AG. The case for intensive statin therapy after acute coronary syndromes. Am J Cardiol. 2005 Sep 05; 96(5A):45F-53F. PMID: 16126023.
      View in: PubMed
    60. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005 May; 26(9):890-6. PMID: 15764620.
      View in: PubMed
    61. Schwartz GG. Statins in acute coronary syndromes: the sooner, the better? Am Heart J. 2005 Mar; 149(3):377-80. PMID: 15864223.
      View in: PubMed
    62. Xu Y, Gen M, Lu L, Fox J, Weiss SO, Brown RD, Perlov D, Ahmad H, Zhu P, Greyson C, Long CS, Schwartz GG. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2005 Mar; 288(3):H1314-23. PMID: 15528232; PMCID: PMC3633522.
    63. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14; 110(11):1406-12. PMID: 15353498.
      View in: PubMed
    64. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004 Jul 27; 110(4):386-91. PMID: 15262833.
      View in: PubMed
    65. Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004 Jul; 148(1):e4. PMID: 15215813.
      View in: PubMed
    66. London MJ, Itani KM, Perrino AC, Guarino PD, Schwartz GG, Cunningham F, Gottlieb SS, Henderson WG. Perioperative beta-blockade: a survey of physician attitudes in the department of Veterans Affairs. J Cardiothorac Vasc Anesth. 2004 Feb; 18(1):14-24. PMID: 14973793.
      View in: PubMed
    67. Schwartz GG, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol. 2003 Nov 01; 92(9):1109-12. PMID: 14583367.
      View in: PubMed
    68. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6. PMID: 12975259.
      View in: PubMed
    69. Xu Y, Lu L, Greyson C, Lee J, Gen M, Kinugawa K, Long CS, Schwartz GG. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes. 2003 May; 52(5):1187-94. PMID: 12716751; PMCID: PMC3633427.
    70. Olsson AG, Schwartz GG, Jonasson L, Linderfalk C. Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol Scand. 2002 Oct; 176(2):147-50. PMID: 12354174.
      View in: PubMed
    71. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002 Sep 24; 106(13):1690-5. PMID: 12270864.
      View in: PubMed
    72. Schwartz GG, Olsson AG. Lipid lowering in acute coronary syndromes: new evidence, new questions. Curr Atheroscler Rep. 2002 Jan; 4(1):1-3. PMID: 11772415.
      View in: PubMed
    73. Olsson AG, Schwartz GG. Early initiation of treatment with statins in acute coronary syndromes. Ann Med. 2002; 34(1):37-41. PMID: 12014432.
      View in: PubMed
    74. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR. Atorvastatin for acute coronary syndromes. JAMA. 2001 Aug 01; 286(5):533-5. PMID: 11476650.
      View in: PubMed
    75. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 04; 285(13):1711-8. PMID: 11277825.
      View in: PubMed
    76. Lu L, Xu Y, Zhu P, Greyson C, Schwartz GG. A common mechanism for concurrent changes of diastolic muscle length and systolic function in intact hearts. Am J Physiol Heart Circ Physiol. 2001 Apr; 280(4):H1513-8. PMID: 11247761; PMCID: PMC3633419.
    77. Waters D, Schwartz GG, Olsson AG. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins? Curr Control Trials Cardiovasc Med. 2001; 2(3):111-114. PMID: 11806782.
      View in: PubMed
    78. Schwartz GG. Exploring new strategies for the management of acute coronary syndromes. Am J Cardiol. 2000 Oct 19; 86(8B):44J-49J; discussion 49J-50J. PMID: 11081448.
      View in: PubMed
    79. Lu L, Gunja-Smith Z, Woessner JF, Ursell PC, Nissen T, Galardy RE, Xu Y, Zhu P, Schwartz GG. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol. 2000 Aug; 279(2):H601-9. PMID: 10924059.
      View in: PubMed
    80. Greyson C, Xu Y, Lu L, Schwartz GG. Right ventricular pressure and dilation during pressure overload determine dysfunction after pressure overload. Am J Physiol Heart Circ Physiol. 2000 May; 278(5):H1414-20. PMID: 10775117; PMCID: PMC3633526.
    81. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 2000 Mar 14; 101(10):1165-71. PMID: 10715264; PMCID: PMC3633448.
    82. Zhu P, Lu L, Xu Y, Greyson C, Schwartz GG. Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2000 Feb; 278(2):H595-603. PMID: 10666092; PMCID: PMC3633424.
    83. Schwartz GG, Reis IM. Is cadmium a cause of human pancreatic cancer? Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):139-45. PMID: 10698473.
      View in: PubMed
    84. Lu L, Xu Y, Greyson CR, Ursell PC, Schwartz GG. Non-elastic deformation of myocardium in low-flow ischemia and reperfusion: ultrastructure-function relations. J Mol Cell Cardiol. 1999 May; 31(5):1157-69. PMID: 10336853.
      View in: PubMed
    85. Xu Y, Lu L, Zhu P, Schwartz GG. beta-adrenergic stimulation induces transient imbalance between myocardial substrate uptake and metabolism in vivo. Am J Physiol. 1998 Dec; 275(6 Pt 2):H2181-90. PMID: 9843818.
      View in: PubMed
    86. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1998 Mar 01; 81(5):578-81. PMID: 9514453.
      View in: PubMed
    87. Lu L, Ko E, Schwartz GG, Chou TM. Transesophageal echocardiography in rats using an intravascular ultrasound catheter. Am J Physiol. 1997 Oct; 273(4 Pt 2):H2078-82. PMID: 9362279.
      View in: PubMed
    88. Greyson C, Xu Y, Cohen J, Schwartz GG. Right ventricular dysfunction persists following brief right ventricular pressure overload. Cardiovasc Res. 1997 May; 34(2):281-8. PMID: 9205541.
      View in: PubMed
    89. Schwartz GG, Xu Y, Greyson C, Cohen J, Lu L. Low-dose inotropic stimulation during left ventricular ischaemia does not worsen post-ischaemic dysfunction. Cardiovasc Res. 1996 Dec; 32(6):1024-37. PMID: 9015405.
      View in: PubMed
    90. Sweeney JP, Schwartz GG. Applying the results of large clinical trials in the management of acute myocardial infarction. West J Med. 1996 Mar; 164(3):238-48. PMID: 8775936; PMCID: PMC1303418.
    91. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995 Sep-Oct; 1(5):195-8. PMID: 21224117.
      View in: PubMed
    92. Greyson C, Garcia J, Mayr M, Schwartz GG. Effects of inotropic stimulation on energy metabolism and systolic function of ischemic right ventricle. Am J Physiol. 1995 May; 268(5 Pt 2):H1821-8. PMID: 7771533.
      View in: PubMed
    93. Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA, Weiner MW, White FC. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation. 1995 Mar 15; 91(6):1814-23. PMID: 7882492.
      View in: PubMed
    94. Schaefer S, Schwartz GG, Steinman S, Garcia J, Trocha SD, Weiner MW, Massie BM. Effects of regional myocardial lidocaine infusion on high energy phosphates. J Mol Cell Cardiol. 1994 Dec; 26(12):1601-11. PMID: 7731055.
      View in: PubMed
    95. Schwartz GG, Greyson C, Wisneski JA, Garcia J. Inhibition of fatty acid metabolism alters myocardial high-energy phosphates in vivo. Am J Physiol. 1994 Jul; 267(1 Pt 2):H224-31. PMID: 8048588.
      View in: PubMed
    96. Schwartz GG, Greyson CR, Wisneski JA, Garcia J, Steinman S. Relation among regional O2 consumption, high-energy phosphates, and substrate uptake in porcine right ventricle. Am J Physiol. 1994 Feb; 266(2 Pt 2):H521-30. PMID: 8141353.
      View in: PubMed
    97. Massie BM, Schwartz GG, Garcia J, Wisneski JA, Weiner MW, Owens T. Myocardial metabolism during increased work states in the porcine left ventricle in vivo. Circ Res. 1994 Jan; 74(1):64-73. PMID: 8261596.
      View in: PubMed
    98. Schwartz GG, Schaefer S, Trocha SD, Garcia J, Steinman S, Massie BM, Weiner MW. Effect of supranormal coronary blood flow on energy metabolism and systolic function of porcine left ventricle. Cardiovasc Res. 1992 Oct; 26(10):1001-6. PMID: 1486583.
      View in: PubMed
    99. Schwartz GG, Steinman SK, Weiner MW, Matson GB. In vivo 31P-NMR spectroscopy of right ventricle in pigs. Am J Physiol. 1992 Jun; 262(6 Pt 2):H1950-4. PMID: 1621852.
      View in: PubMed
    100. Schwartz GG, Steinman S, Garcia J, Greyson C, Massie B, Weiner MW. Energetics of acute pressure overload of the porcine right ventricle. In vivo 31P nuclear magnetic resonance. J Clin Invest. 1992 Mar; 89(3):909-18. PMID: 1541681; PMCID: PMC442937.
    101. Schaefer S, Schwartz GG, Wisneski JA, Trocha SD, Christoph I, Steinman SK, Garcia J, Massie BM, Weiner MW. Response of high-energy phosphates and lactate release during prolonged regional ischemia in vivo. Circulation. 1992 Jan; 85(1):342-9. PMID: 1728466.
      View in: PubMed
    102. Schwartz GG, Schaefer S, Trocha SD, Steinman S, Gober J, Garcia J, Massie B, Weiner MW. Metabolic and functional consequences of blunted myocardial reactive hyperemia. Am J Physiol. 1991 Sep; 261(3 Pt 2):H892-900. PMID: 1887933.
      View in: PubMed
    103. Schwartz GG, Schaefer S, Gober J, Meyerhoff DJ, Smekal A, Massie B, Weiner MW. Myocardial high-energy phosphates in reactive hyperemia. Am J Physiol. 1990 Oct; 259(4 Pt 2):H1190-6. PMID: 2221125.
      View in: PubMed
    104. Schwartz GG, Schaefer S, Meyerhoff DJ, Gober J, Fochler P, Massie B, Weiner MW. Dynamic relation between myocardial contractility and energy metabolism during and following brief coronary occlusion in the pig. Circ Res. 1990 Aug; 67(2):490-500. PMID: 2376083.
      View in: PubMed
    105. Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B. In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol. 1990 May 01; 65(16):1154-61. PMID: 2139540.
      View in: PubMed
    106. Schaefer S, Schwartz GG, Gober JR, Wong AK, Camacho SA, Massie B, Weiner MW. Relationship between myocardial metabolites and contractile abnormalities during graded regional ischemia. Phosphorus-31 nuclear magnetic resonance studies of porcine myocardium in vivo. J Clin Invest. 1990 Mar; 85(3):706-13. PMID: 2312722; PMCID: PMC296486.
    107. Schwartz GG, McHale PA, Greenfield JC. Hyperemic response of the coronary circulation to brief diastolic occlusion in the conscious dog. Circ Res. 1982 Jan; 50(1):28-37. PMID: 7053875.
      View in: PubMed
    108. Schwartz GG, McHale PA, Greenfield JC. Coronary vasodilation after a single ventricular extra-activation in the conscious dog. Circ Res. 1982 Jan; 50(1):38-46. PMID: 7053876.
      View in: PubMed
    Schwartz's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)